Dawnrays Pharmaceutical (Holdings) Ltd is an investment holding company mainly engaged in the development, manufacture and sale of non-patented drugs. The Company operates its business through two segments. The finished drugs segment is engaged in the manufacture and sale of finished drugs. The intermediates and bulk medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines.

Employees

1,081

Sector

Pharmaceuticals

Calendar

08-28 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-14	HK$1.030	+0.98%	184,000
26-08-13	HK$1.020	+0.99%	172,000
26-08-12	HK$1.010	+2.02%	84,000
26-08-11	HK$0.9900	0.00%	8,000
26-08-10	HK$0.9900	-1.00%	264,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. 04:08:36 2026-08-14 EDT			5-day change	1st Jan Change
1.030 ^HKD	+0.98%		+3.00%	-15.57%

05-29	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg	CI
05-22	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025	CI

Market Cap	1.33B 1.55B 198M 171M 160M 146M 274M 18.9B 279M 1.88B 735M 9.46B 742M 726M 31.45B	P/E 2024	3.06x	P/E 2025	7.83x
Enterprise Value	-394M -459M -58.48M -50.51M -47.46M -43.17M -81.16M -5.59B -82.49M -556M -217M -2.8B -220M -215M -9.31B	EV / Sales 2024	0.14x	EV / Sales 2025	-0.06x
Free-Float	32.62%	Yield 2024	5.16%	Yield 2025	5.16%

05-29	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg	CI
05-22	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025	CI
03-27	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-27	Dawnrays Pharmaceutical (Holdings) final dividend of HK$0.048 per share	RE
03-27	Dawnrays Pharmaceutical Limited Proposes Final Cash Dividend for the Year Ended December 31, 2025, Payable on June 12, 2026	CI
25-08-22	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-22	Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2025, Payable on 03 October 2025	CI
25-08-22	Dawnrays pharmaceutical reports HY net income attributable of RMB104.6 mln	RE
25-07-31	Dawnrays Pharmaceutical Limited Announces Appointment of Hu Shuo as Non-Executive Director with Effect from 1 August 2025	CI
25-05-23	Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended 31 December 2024	CI
25-05-23	Dawnrays Pharmaceutical Limited Declares Special Dividend for the Year Ended 31 December 2024	CI
25-03-28	Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million	RE
25-03-28	Dawnrays Pharmaceutical Limited Proposes Special Dividend for the Year Ended December 31, 2024, Payable on 12 June 2025	CI

21-04-19	Dawnrays Pharmaceutical : Form of proxy for use at the Annual General Meeting of the Company to be held on Friday, 28 May 2021 (or at any adjournment thereof)	PU
21-04-19	Dawnrays Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	PU
20-09-23	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
20-09-22	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
20-09-21	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU

Dawnrays Pharmaceutical (Holdings) Limited Stock

Stocks

2348

KYG2687M1006

Pharmaceuticals

Valuation: Dawnrays Pharmaceutical (Holdings) Limited

Chart: Dawnrays Pharmaceutical (Holdings) Limited

Latest news : Dawnrays Pharmaceutical (Holdings) Limited

Press Releases: Dawnrays Pharmaceutical (Holdings) Limited

Quotes and Performance

Course Extremes

Managers and Directors: Dawnrays Pharmaceutical (Holdings) Limited

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+0.98%
1 week	+3.00%
Current month	-0.96%
1 month	+4.04%
3 months	-8.04%
6 months	-12.71%
Current year	-15.57%

1 week	0.98	1.05
1 month	0.98	1.06
Current year	0.98	1.22
1 year	0.98	1.39
3 years	0.98	1.47
5 years	0.98	1.82
10 years	0.84	2.88

Manager	Title	Age	Since
Li Wei Yu CEO	Chief Executive Officer	56	2024-09-12
Yi jun Wu DFI	Director of Finance/CFO	61	-
Michelle Li IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Kei Ling Li CHM	Chairman	77	2002-09-30
Yung Lai Hung BRD	Director/Board Member	81	2002-09-30
Hong Man Leung BRD	Director/Board Member	51	2005-10-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/24/25	Kei Ling Li	Other	Chairman	8,000	0.0005%
11/24/25	Fortune United Group Ltd	Other	Company	8,000	0.0005%
11/3/25	Yung Lai Hung	Other	Director	52,000	0.0035%

	2024	2025
Net sales	1.06B 1.23B 157M 136M 128M 116M 218M 15.03B 222M 1.5B 585M 7.53B 590M 577M 25.02B	1.23B 1.43B 182M 158M 148M 135M 253M 17.45B 257M 1.74B 679M 8.74B 685M 670M 29.04B
Net income	565M 657M 83.76M 72.35M 67.98M 61.83M 116M 8.01B 118M 797M 311M 4.01B 314M 308M 13.33B	214M 249M 31.72M 27.4M 25.75M 23.42M 44.03M 3.03B 44.75M 302M 118M 1.52B 119M 117M 5.05B
Net Debt	-1.57B -1.83B -233M -201M -189M -172M -324M -22.3B -329M -2.22B -867M -11.17B -876M -857M -37.11B	-1.73B -2.01B -256M -221M -208M -189M -355M -24.49B -361M -2.44B -952M -12.26B -962M -941M -40.75B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED	+0.98%	+3.00%	-25.36%	-14.17%	196M
ELI LILLY AND COMPANY	-1.69%	-0.26%	+72.79%	+119.82%	1,078B
JOHNSON & JOHNSON	-0.29%	+0.63%	+49.31%	+50.42%	632B
ABBVIE INC.	-0.28%	+1.37%	+21.85%	+63.79%	443B
ROCHE HOLDING AG	-1.99%	-3.32%	+41.98%	+34.08%	356B
NOVARTIS AG	-1.05%	-2.81%	+24.22%	+34.67%	289B
ASTRAZENECA PLC	-2.12%	-3.67%	-1.09%	+3.11%	245B
AMGEN INC.	-0.86%	+0.49%	+42.25%	+58.23%	226B
NOVO NORDISK A/S	-1.19%	-3.41%	-9.18%	-52.41%	204B
GILEAD SCIENCES, INC.	+0.02%	+3.59%	+15.94%	+72.81%	171B
Average	-0.85%	+1.49%	+23.27%	+37.04%	364.39B
Weighted average by Cap.	-1.13%	+1.30%	+41.54%	+62.33%